t
PATIENT SAFETY
A growing market for safety syringes
Almost a decade since sharps legislation was passed in Europe and the US, compliance still has a way to go to reach mandatory legal requirements in hospitals - and even more so in non-hospital locations. To understand future demand for safety syringes, George I’ons, head of product strategy and insights at Owen Mumford examines research into trends and drivers surrounding safety-device take up.
Administration of medication by injection in non-hospital settings is increasingly becoming more of a norm in the EU and the US. A number of elements are driving this trend, first and foremost the need to reduce the burden on pressurised hospitals to provide treatment for chronic diseases that often require daily, typically subcutaneous, injection. With more and more people administering treatment themselves in their home each day, or receiving treatment from carers and visiting nurses, the issue of needlestick safety during injection has spread far beyond the strictly clinical setting.
This trend is closely connected to the growth of the safety syringe market, which, according to one analyst,1
is expected to
grow at a compound annual growth rate (CAGR) of 8.9% between 2018 and 2023. Looking specifically at safety-engineered pre-filled syringes, the market is projected to grow from $551 million in 2018, to a staggering $869 m by 2023 (9.6% CAGR). This means that safety-engineered pre-filled syringes will dominate the market, with approximately 76% share of the total pre-filled demand in 2023. This article looks at some of the main drivers for this growth in the EU and US.
Hospital settings are well regulated by the EU Directive 2010/52/EU on the prevention of sharps injuries, implemented in 2014 in Europe, and by the 6 November 2000 Needlestick Safety and Prevention Act2
in
the US. With needlestick injuries falling by around 30% in the US, studies show that half of non-hospital healthcare settings are in violation of OSHA law.3
Non-clinical
settings pose an even greater obstacle; and over two fifths of registered nurses are now employed in non-hospital settings.4 The US Bureau of Labor Statistics projects “personal care aide” and “home care aide” to be the second and third fastest
NOVEMBER 2019
growing jobs during 2012–2022.5 Importantly, although home care aides typically do not use sharps themselves, there is a body of evidence showing that they are sometimes pressured by a client or family member to do so – in spite of this.6
Safety-engineered pre-filled syringes will dominate the market, with approximately 76% share of the total pre-filled demand in 2023.
Reports also highlight that sharps injuries to home care aides in a home care setting are often caused by incorrect disposal of sharps. Both in Europe and the US, in fact, it is the legal duty of the employer or contractor to evaluate a risk assessment for sharps injury within the work environment and protect their staff. This also applies to staff working outside a clinical environment and visiting an outpatient in their home, providing one explanation for the increasing demand for safety engineered devices typically used in the home.
Self administering
With home care increasingly taking centre stage, and patients being encouraged to self- administer to manage their conditions, and sharps prevention practices compliance as low as 60% according to the European Biosafety Network,7
disposable delivery
WWW.CLINICALSERVICESJOURNAL.COM I 71
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100 |
Page 101 |
Page 102 |
Page 103 |
Page 104
